[
    [
        {
            "time": "2023-10-15",
            "original_text": "FDA To Miss Action Dates For AbbVie's Upadacitinib Application For Psoriatic Arthritis, Ankylosing Spondylitis",
            "features": {
                "keywords": [
                    "FDA",
                    "AbbVie",
                    "Upadacitinib",
                    "Psoriatic Arthritis",
                    "Ankylosing Spondylitis"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "FDA To Miss Action Dates For AbbVie's Upadacitinib Application For Psoriatic Arthritis, Ankylosing Spondylitis",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-15",
            "original_text": "AbbVie Provides Update Regarding RINVOQ速 (upadacitinib) in Psoriatic Arthritis and Ankylosing Spondylitis in the U.S.",
            "features": {
                "keywords": [
                    "AbbVie",
                    "RINVOQ",
                    "Upadacitinib",
                    "Psoriatic Arthritis",
                    "Ankylosing Spondylitis",
                    "U.S."
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie Provides Update Regarding RINVOQ速 (upadacitinib) in Psoriatic Arthritis and Ankylosing Spondylitis in the U.S.",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-15",
            "original_text": "3 High-Yield Stocks With Secure Payouts",
            "features": {
                "keywords": [
                    "High-Yield",
                    "Stocks",
                    "Payouts"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "dividends"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "3 High-Yield Stocks With Secure Payouts",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-15",
            "original_text": "AbbVie Slips on FDA Delay in Arthritis-Drug Action Dates",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Slips",
                    "FDA",
                    "Delay",
                    "Arthritis-Drug"
                ],
                "sentiment_score": -0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "AbbVie Slips on FDA Delay in Arthritis-Drug Action Dates",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-15",
            "original_text": "AbbVie Inc. (NYSE:ABBV) is Finding Balance between Dividends and Growth",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Dividends",
                    "Growth"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "finance"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie Inc. (NYSE:ABBV) is Finding Balance between Dividends and Growth",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-15",
            "original_text": "CHMP Recommends Approval of RINVOQ速 (upadacitinib) for the Treatment of Atopic Dermatitis",
            "features": {
                "keywords": [
                    "CHMP",
                    "RINVOQ",
                    "Upadacitinib",
                    "Atopic Dermatitis",
                    "Approval"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "CHMP Recommends Approval of RINVOQ速 (upadacitinib) for the Treatment of Atopic Dermatitis",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]